Literature DB >> 33390943

Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models.

Daniil Polykovskiy1, Alexander Zhebrak1, Benjamin Sanchez-Lengeling2, Sergey Golovanov3, Oktai Tatanov3, Stanislav Belyaev3, Rauf Kurbanov3, Aleksey Artamonov3, Vladimir Aladinskiy1, Mark Veselov1, Artur Kadurin1, Simon Johansson4, Hongming Chen4, Sergey Nikolenko1,3,5, Alán Aspuru-Guzik6,7,8,9, Alex Zhavoronkov1.   

Abstract

Generative models are becoming a tool of choice for exploring the molecular space. These models learn on a large training dataset and produce novel molecular structures with similar properties. Generated structures can be utilized for virtual screening or training semi-supervized predictive models in the downstream tasks. While there are plenty of generative models, it is unclear how to compare and rank them. In this work, we introduce a benchmarking platform called Molecular Sets (MOSES) to standardize training and comparison of molecular generative models. MOSES provides training and testing datasets, and a set of metrics to evaluate the quality and diversity of generated structures. We have implemented and compared several molecular generation models and suggest to use our results as reference points for further advancements in generative chemistry research. The platform and source code are available at https://github.com/molecularsets/moses.
Copyright © 2020 Polykovskiy, Zhebrak, Sanchez-Lengeling, Golovanov, Tatanov, Belyaev, Kurbanov, Artamonov, Aladinskiy, Veselov, Kadurin, Johansson, Chen, Nikolenko, Aspuru-Guzik and Zhavoronkov.

Entities:  

Keywords:  benchmark; deep learning; distribution learning; drug discovery; generative models

Year:  2020        PMID: 33390943      PMCID: PMC7775580          DOI: 10.3389/fphar.2020.565644

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  32 in total

Review 1.  New Insights Into Drug Repurposing for COVID-19 Using Deep Learning.

Authors:  Chun Yen Lee; Yi-Ping Phoebe Chen
Journal:  IEEE Trans Neural Netw Learn Syst       Date:  2021-10-27       Impact factor: 10.451

2.  Predicting novel drug candidates against Covid-19 using generative deep neural networks.

Authors:  Santhosh Amilpur; Raju Bhukya
Journal:  J Mol Graph Model       Date:  2021-10-13       Impact factor: 2.518

Review 3.  De novo molecular drug design benchmarking.

Authors:  Lauren L Grant; Clarissa S Sit
Journal:  RSC Med Chem       Date:  2021-06-03

4.  LIMO: Latent Inceptionism for Targeted Molecule Generation.

Authors:  Peter Eckmann; Kunyang Sun; Bo Zhao; Mudong Feng; Michael K Gilson; Rose Yu
Journal:  Proc Mach Learn Res       Date:  2022-07

5.  Design of SARS-CoV-2 Main Protease Inhibitors Using Artificial Intelligence and Molecular Dynamic Simulations.

Authors:  Lars Elend; Luise Jacobsen; Tim Cofala; Jonas Prellberg; Thomas Teusch; Oliver Kramer; Ilia A Solov'yov
Journal:  Molecules       Date:  2022-06-22       Impact factor: 4.927

Review 6.  Deep generative models for peptide design.

Authors:  Fangping Wan; Daphne Kontogiorgos-Heintz; Cesar de la Fuente-Nunez
Journal:  Digit Discov       Date:  2022-03-31

7.  Memory augmented recurrent neural networks for de-novo drug design.

Authors:  Naveen Suresh; Neelesh Chinnakonda Ashok Kumar; Srikumar Subramanian; Gowri Srinivasa
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

8.  Exploring Novel Biologically-Relevant Chemical Space Through Artificial Intelligence: The NCATS ASPIRE Program.

Authors:  Katharine K Duncan; Dobrila D Rudnicki; Christopher P Austin; Danilo A Tagle
Journal:  Front Robot AI       Date:  2020-01-10

Review 9.  Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence.

Authors:  José T Moreira-Filho; Arthur C Silva; Rafael F Dantas; Barbara F Gomes; Lauro R Souza Neto; Jose Brandao-Neto; Raymond J Owens; Nicholas Furnham; Bruno J Neves; Floriano P Silva-Junior; Carolina H Andrade
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

10.  Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors.

Authors:  Noah R Flynn; Michael D Ward; Mary A Schleiff; Corentine M C Laurin; Rohit Farmer; Stuart J Conway; Gunnar Boysen; S Joshua Swamidass; Grover P Miller
Journal:  Metabolites       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.